Tags: Cancer | melanoma | skin | cancer | therapy | fda

FDA to Fast Track New Therapy for Melanoma

FDA to Fast Track New Therapy for Melanoma
(Copyright Stock Photo Secrets)

Friday, 22 December 2017 10:20 AM

The U.S. Food and Drug Administration has granted priority review for Novartis's Tafinlar in combination with Mekinist for treating some patients with advanced melanoma, the Swiss drugmaker said on Friday.

The review covers the combination therapy for the adjuvant treatment of patients with stage III melanoma with BRAF V600E or V600K mutations following complete resection.

In October, the FDA also granted breakthrough therapy designation to Tafinlar in combination with Mekinist for the adjuvant treatment of patients with stage III melanoma with a BRAF V600 mutation following complete resection, the company said in a statement.

© 2021 Thomson/Reuters. All rights reserved.


Health-News
The FDA has granted priority review for Novartis's Tafinlar in combination with Mekinist for treating some patients with advanced melanoma.
melanoma, skin, cancer, therapy, fda
94
2017-20-22
Friday, 22 December 2017 10:20 AM
Newsmax Media, Inc.
 
Newsmax TV Live

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved